Bortecad 2.5mg - Bortezomib Injection

Bortecad 2.5mg Injection is a chemotherapy medication that belongs to the class of medicines called proteasome inhibitors. It consists of the active ingredient Bortezomib. It is indicated for the treatment of multiple myeloma and mantle cell lymphoma. Multiple myeloma refers to the cancerous progression of plasma cells that are predominant in the bone marrow. Mantle cell lymphoma is a less common cancer affecting the lymph nodes. This medication is concomitantly used with other chemotherapy medicines like pegylated liposomal doxorubicin, rituximab, cyclophosphamide, doxorubicin, dexamethasone, prednisolone or thalidomide for patients who have not started treatment and are ineligible for blood stem cell transplant. 

The common side effects likely associated with Bortecad 2.5mg Injection are Pneumonia, loss of appetite, sensitivity, tingling and burning sensation of the skin, nausea, vomiting, diarrhea, mouth ulcers, constipation, muscle and bone pain, hair loss, fever, infections, itching, redness, dehydration, stomach problems, etc., Inform your physician if these side effects disturb or persist in you.  

Inform your doctor if you are allergic to Bortecad 2.5mg  Injection and its ingredients. Do not use this medication if you have severe lung or heart problems. Before starting treatment with this medication, let your physician know if you are suffering from neuropathy (nerves malfunction), cardiac disorders, severe lung problems, pulmonary disorders, posterior reversible encephalopathy syndrome disorders, gastrointestinal disorders, thrombocytopenia (a low platelet count), neutropenia (low white blood cell count), tumor lysis syndrome (metabolic abnormalities that can occur as a complication during the treatment of cancer), hepatic disorders. Inform your doctor of diabetes because this Injection can affect your blood glucose levels.